We are pleased to disclose the further expansion project in our Indian manufacturing site aimed to increase the capacity of Rifaximin and Rifampicin. Olon has officially kicked off the project with a ground-breaking ceremony.
Thanks to the new investment, Olon is going to build an additional production unit at its Mahad site (India) that significantly expands the total capacity of producing rifa’s family APIs, and notably both Rifaximin and Rifampicin, supporting the global market demand for these products.
Olon site in Mahad, fully integrated into the platform of 11 plants worldwide with production of more than 20 APIs and intermediates for the rest of the group by synthetic route, has developed a particular leadership position in the fermentation production of the rifa’s family (Rifampicin, Rifaximin, Rifapentine) and its intermediates (Rifa S, Rifa O).
“This expansion strengthens Olon’s commitment to meeting the growing global demand for these critical antibiotics,” said Marcello Buson, SVP Global Operations, “By leveraging our expertise and expanding our Mahad facility, we can ensure a reliable and consistent supply of high-quality Rifaximin and Rifampicin for patients worldwide.”
Olon Group, a world leader in the production of APIs, recently announced a multi-year expansion plan for the Indian production site, which will see its total production capacity of both intermediates and finished APIs by 45% overall.